V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Replimune Group Executive Compensation (FY26)

REPL · Executive and director compensation, fiscal 2022 to 2026
Chief executive, fiscal 2026
◇
Sushil Patel
Latest say-on-pay support
=
September 15, 2026
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.
Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.

The paid brief on Replimune Group

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
Data as of October 22, 2026Latest filing (8-K): September 16, 2026
7 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Replimune Group brief$1,500Get the executive brief
Velarion Member, one year
185 figures on this page: 181 cited to the filing that reported them, 4 calculated from figures it prints. See the citations

More on Replimune Group

Five data products on this company. Each one is requested through the developer setup page.
What changed from fiscal 2025 to fiscal 2026
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Sushil Patel: $3,697,661 → $5,845,982 (58.1% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Replimune Group's chief executive and what were they paid?
Sushil Patel, Chief Executive Officer, received $5,845,982 in total compensation for fiscal 2026. Patel's total moved 58.1% higher from the $3,697,661 reported for fiscal 2025.
What was Replimune Group's say-on-pay result?
Shareholders supported the say-on-pay proposal with 98.7% of votes cast for or against in favor at the meeting held September 15, 2026 for fiscal 2026.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Sushil Patel
Chief Commercial Officer
◇—◇◇◇—◇◇
Philip Astley-Sparke
Chief Executive Officer
◇—◇◇◇——◇
Robert Coffin
President and Chief Research & Development Officer
◇—◇◇◇——◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Emily Hill
Chief Financial Officer
◇—◇◇◇——◇
Konstantinos Xynos
Chief Medical Officer
◇—◇◇◇—◇◇
Sushil Patel
Chief Executive Officer
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Sushil Patel
Chief Executive Officer
◇—◇◇◇—◇◇
Konstantinos Xynos
Chief Medical Officer
◇—◇◇◇—◇◇
Emily Hill
Chief Financial Officer
◇—◇◇◇——◇
Fiscal 2026
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Sushil Patel
Chief Executive Officer
◇—◇◇◇—◇◇
Konstantinos Xynos
Chief Medical Officer
◇—◇◇◇—◇◇
Emily Hill
Chief Financial Officer
◇—◇◇◇——◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Emily HillPSU——◇———◇
Konstantinos XynosPSU——◇———◇
Sushil PatelRSU———◇——◇
Sushil PatelOPTION———◇—◇◇
Sushil PatelPSU——◇———◇
Fiscal 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2026 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Konstantinos XynosOption◇—◇—
Option◇—◇—
RSU◇◇——
Option◇—◇—
Option◇—◇—
Option◇—◇—
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇—
Emily HillOption◇—◇—
Option◇—◇—
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇—
Option◇—◇—
RSU◇◇——
Sushil PatelOption◇—◇—
RSU◇◇——
RSU◇◇——
Option◇—◇—
Option◇—◇—
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇—
Option◇—◇—
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2026
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Dieter Weinand
◇—◇———◇
Joseph Slattery
◇—◇———◇
Christy Oliger
◇—◇———◇
Kapil Dhingra
◇—◇———◇
Veleka Peeples-Dyer
◇—◇———◇
Paolo Pucci
◇—◇———◇
Madhavan Balachandran
◇—◇———◇
Michael Goller
◇—————◇
Sushil Patel, Philip Astley-Sparke and Hyam Levitsky served on the board in fiscal 2026 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Total board retainer◇
Equity is delivered as Options.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2026September 15, 2026=◇◇◇
2025September 3, 2025=◇◇◇
2024September 4, 2024=◇◇◇
2023September 4, 2024=◇◇◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Sushil Patel (Chief Executive Officer), FY2026 total compensation $5,845,982 (base salary $700,000) [exec_comp, SEC accession 0001104659-26-087650, filed 2026-07-29]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Tell me when Replimune Group files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Replimune Group disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Replimune Group's disclosed peer group is defensible, who names Replimune Group back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
185 figures on this page: 181 cited to the filing that reported them, 4 calculated from figures it prints.
181 cited to the filing
4 calculated from the filing

Documents cited

  1. 0001104659-26-108243
    Proposal No. 2 – Say on Pay Proposal : The compensation of the Company’s named executive officers for the fiscal year ended March 31, 2026 was approved on a non-binding advisory basis.
  2. 0001104659-26-087650
    DIRECTOR COMPENSATION · EXECUTIVE COMPENSATION · Outstanding Equity Awards at Fiscal Year End · Summary Compensation Table
  3. 0001104659-25-087464
    Proposal No. 3 – Say on Pay Proposal : The compensation of the Company’s named executive officers for the fiscal year ended March 31, 2025 was approved on a non-binding advisory basis.
  4. 0001104659-25-070833
    Summary Compensation Table
  5. 0001104659-24-097365
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0001104659-24-081167
    Summary Compensation Table
  7. 0001104659-22-082980
    Summary Compensation Table
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Replimune Group executive compensation, FY2022–FY2026.” https://intel.velarion.ai/comp/REPL (accessed 2026).
Short form: data: Velarion

The paid brief for Replimune Group

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
7 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Replimune Group and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy